Opportunity Information: Apply for PAR 21 240
The NIH, through the National Center for Complementary and Integrative Health (NCCIH), is offering a discretionary grant opportunity (PAR-21-240) to fund early-phase, feasibility clinical trials of complementary and integrative health approaches that use physical and/or psychological therapeutic inputs, commonly referred to as mind and body interventions. The central purpose is not to prove that an intervention works, but to generate the practical, real-world evidence needed to responsibly design a later, larger-scale study such as a controlled cohort study, a clinical efficacy or effectiveness trial, or a pragmatic clinical trial. In other words, this program is meant to help research teams answer the "Can we do this well, and how should we do it?" questions that must be settled before launching an expensive, definitive trial.
Projects supported under this announcement are expected to focus on conditions that NCCIH has already identified as high priority research topics. The feasibility work should directly address gaps in knowledge that would otherwise weaken a future full-scale clinical trial application. Examples of the kinds of questions NCCIH expects investigators to tackle include whether a specific mind and body intervention is feasible and acceptable in a target population when little or no prior published data exist, whether an existing intervention needs to be adapted for a particular group, and how to refine the intervention parameters (such as the most appropriate session frequency, intensity, or duration). The FOA also highlights operational feasibility, such as whether recruitment strategies are realistic, whether retention is likely to be strong enough to support a larger trial, and whether data collection procedures are workable and acceptable for participants and study sites. It can also support refining and testing the feasibility of protocolized multimodal interventions (interventions with more than one coordinated component) and evaluating whether proposed control conditions are acceptable and whether participants are likely to adhere to them, which is often a major stumbling block in mind and body research.
At the same time, the announcement draws clear boundaries around what it will not fund. It will not support randomized clinical trials designed to test, demonstrate, or determine efficacy or effectiveness. It also will not fund repetitive feasibility or acceptability studies that have essentially already been done, meaning applicants need to show that their proposed feasibility questions are still genuinely unanswered for the intervention and population they intend to study. Additionally, applications that primarily aim to write a protocol, produce a manual of operations, or build general trial infrastructure without conducting the kind of feasibility clinical trial work described are considered nonresponsive to the opportunity. The expectation is that the feasibility trial will produce actionable results that inform a subsequent larger trial with credible potential to matter for public health.
This opportunity uses the R34 funding mechanism and is categorized under health research (CFDA 93.213). The listed award ceiling is $225,000. It is open to a wide range of U.S.-based applicants, including state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses. The FOA also explicitly includes categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, and eligible federal agencies, as well as U.S. territories or possessions. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. Foreign components, as defined by NIH policy, are not allowed.
Key administrative details include that the sponsoring agency is the National Institutes of Health, the opportunity was created on June 14, 2021, and the original closing date listed is December 21, 2023. Overall, the program is best viewed as a structured on-ramp to a later definitive trial: it supports the careful testing of trial readiness (intervention delivery, participant engagement, recruitment logistics, measurement procedures, and control condition practicality) so that the next-stage study is both scientifically compelling and operationally realistic.Apply for PAR 21 240
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213.
- This funding opportunity was created on 2021-06-14.
- Applicants must submit their applications by 2023-12-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $225,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this NIH grant opportunity?
This is an NIH discretionary funding opportunity from the National Center for Complementary and Integrative Health (NCCIH), listed as PAR-21-240. It supports early-phase, feasibility clinical trials focused on complementary and integrative health approaches that use physical and/or psychological therapeutic inputs (commonly called mind and body interventions).
What is the main purpose of this funding?
The goal is to generate practical, real-world feasibility evidence to responsibly design a later, larger-scale study. The program is meant to help teams answer trial-readiness questions such as: Can we do this well, and how should we do it? It is not primarily intended to prove that an intervention works.
What type of studies does this FOA support?
The FOA supports early-phase feasibility clinical trials of mind and body interventions. These studies are expected to produce actionable findings that inform the design of a subsequent larger trial (for example, a controlled cohort study, a clinical efficacy or effectiveness trial, or a pragmatic clinical trial).
What kinds of interventions are in scope?
Interventions must be complementary and integrative health approaches using physical and/or psychological therapeutic inputs, described as mind and body interventions. The FOA also allows work on protocolized multimodal interventions (interventions with more than one coordinated component).
What does NCCIH expect investigators to learn or demonstrate in the feasibility trial?
Projects should address feasibility gaps that would otherwise weaken a future full-scale clinical trial application. Examples include determining whether the intervention is feasible and acceptable in a target population when little or no prior published data exist, whether an existing intervention must be adapted for a specific group, and how to refine intervention parameters such as session frequency, intensity, or duration.
Does the FOA support operational feasibility work (recruitment, retention, procedures)?
Yes. The FOA explicitly highlights operational feasibility, including whether recruitment strategies are realistic, whether retention is likely to be strong enough to support a larger trial, and whether data collection procedures are workable and acceptable for participants and study sites.
Can this opportunity be used to test control conditions?
Yes. The FOA includes evaluating whether proposed control conditions are acceptable and whether participants are likely to adhere to them, which can be a major challenge in mind and body intervention research.
Are projects required to focus on specific health conditions?
Yes. Supported projects are expected to focus on conditions that NCCIH has already identified as high priority research topics.
Is the program intended to demonstrate efficacy or effectiveness?
No. The announcement draws a clear boundary that it will not support randomized clinical trials designed to test, demonstrate, or determine efficacy or effectiveness.
Will NCCIH fund feasibility studies that are repetitive or already answered?
No. The FOA will not fund repetitive feasibility or acceptability studies that have essentially already been done. Applicants are expected to show that their feasibility questions are still genuinely unanswered for the intervention and population they plan to study.
Can the grant be used mainly to write a protocol or build general trial infrastructure?
No. Applications that primarily aim to write a protocol, produce a manual of operations, or build general trial infrastructure without conducting the feasibility clinical trial work described are considered nonresponsive.
What should the feasibility trial produce by the end of the project?
The expectation is that the feasibility trial will yield actionable results that directly inform a subsequent larger trial and that the next-stage study has credible potential to matter for public health.
What funding mechanism does this opportunity use?
This opportunity uses the NIH R34 funding mechanism.
What is the CFDA number and category for this opportunity?
It is categorized under health research with CFDA 93.213.
What is the maximum award amount listed?
The listed award ceiling is $225,000.
Who is eligible to apply?
The FOA is open to a wide range of U.S.-based applicants, including state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses.
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA explicitly includes categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, and eligible federal agencies, as well as U.S. territories or possessions.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible to apply.
Can a U.S. organization include a non-U.S. component or foreign component?
No. Non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed.
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH).
When was the opportunity created and when was it originally set to close?
The opportunity was created on June 14, 2021, and the original closing date listed is December 21, 2023.
How should applicants think about this program strategically?
This program is best viewed as a structured on-ramp to a later definitive trial. It supports careful testing of trial readiness (intervention delivery, participant engagement, recruitment logistics, measurement procedures, and control condition practicality) so that the next-stage study is both scientifically compelling and operationally realistic.
Browse more opportunities from the same category: Health
Next opportunity: Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
Previous opportunity: REQUEST FORINFORMATION - Equitable and Resilient Finance
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 240
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 240) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 21 243 Funding Number: PAR 21 243 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) Apply for PAR 21 242 Funding Number: PAR 21 242 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) Apply for PAR 21 241 Funding Number: PAR 21 241 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Role of Adaptive Immunity in Etiology of Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional) Apply for RFA AG 22 017 Funding Number: RFA AG 22 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed) Apply for RFA AG 22 018 Funding Number: RFA AG 22 018 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Disaster Risk Management Apply for 720 663 21 RFI 00007 Funding Number: 720 663 21 RFI 00007 Agency: Ethiopia USAID-Addis Ababa Category: Health Funding Amount: $8,000,000 |
| Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional) Apply for PAR 21 250 Funding Number: PAR 21 250 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed) Apply for PAR 21 249 Funding Number: PAR 21 249 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required) Apply for RFA MH 21 241 Funding Number: RFA MH 21 241 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional) Apply for RFA DC 22 001 Funding Number: RFA DC 22 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed) Apply for PAR 21 269 Funding Number: PAR 21 269 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required) Apply for RFA MH 21 240 Funding Number: RFA MH 21 240 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed) Apply for PAR 21 204 Funding Number: PAR 21 204 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Investigators to Promote Workforce Diversity in Genomics and other Health-Related Research (R01 Clinical Trial Optional) Apply for RFA HG 21 025 Funding Number: RFA HG 21 025 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional) Apply for RFA AG 22 027 Funding Number: RFA AG 22 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed) Apply for RFA AG 22 022 Funding Number: RFA AG 22 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) Apply for PAR 21 263 Funding Number: PAR 21 263 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) Apply for PAR 21 264 Funding Number: PAR 21 264 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technology Development for Single-Molecule Protein Sequencing (R01 Clinical Trial not allowed) Apply for RFA HG 21 001 Funding Number: RFA HG 21 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed) Apply for RFA HG 21 002 Funding Number: RFA HG 21 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 240", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
